UNSPSC 51383309: Alclofenac

This classification denotes an anti-inflammatory agent with the molecular formula C11H11ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M9CP5H21N8, chemically known as benzeneacetic acid, 3-chloro-4-(2-propenyloxy)- but generally known as alclofenac, which bears US NIH Compound Identifier 30951. Alclofenac comes in many forms, including epoxide, monoethanolamine complex, and sodium. European Medicines Agency schedules Alclofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05299MIG.

UNSPSC 51383309 Alclofenac (Commodity) represents a pharmaceutical product category, but the recent state and local opportunities tagged under this code reflect a broader pattern of government procurement for generic pharmaceuticals, over-the-counter products, and opioid-response medications rather than alclofenac specifically. State and local buyers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. The actual work being solicited encompasses supply agreements for generic multi-source drugs and OTC products distributed through authorized wholesalers, direct-to-manufacturer prescription programs to bypass traditional pharmacy benefit manager channels, and targeted public health procurement such as naloxone and drug deactivation systems for community health initiatives. Issuing bodies vary from single-jurisdiction health departments to statewide cooperative purchasing vehicles serving multiple states.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring unit pricing and vendor compliance with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission released RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct state-to-manufacturer relationships outside traditional PBM and GPO arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring manufacturers to supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson with pricing evaluation weighted 75 percent on competitiveness, compliance with cGMP and Drug Supply Chain Security Act certification, and participation in at least two of three authorized wholesaler networks. Contract terms typically span two years with renewal options, and vendors must maintain substantial commercial general liability and professional liability insurance.